Forum for Science, Industry and Business

Sponsored by:     3M 
Search our Site:

 

Hemoglobin-Based Agent Reduces Need for Transfusion During Heart Surgery

13.12.2002


A Phase II clinical trial conducted at Duke University Medical Center and five other U.S. institutions has shown that an agent made of purified human hemoglobin appears safe and may be effective when used instead of transfused human blood to replace blood lost during heart surgery.



If the benefits of the agent, known as hemoglobin raffimer, are proven in subsequent Phase III clinical trials, physicians would not need to use as much donated blood during surgery, the researchers said. An estimated 20 percent of all human blood transfused in the U.S. is associated with heart surgery, so the Duke researchers believe that an efficient ?oxygen therapeutic? could play an important role in reducing the need for transfused blood.

The results of the trial were published today (Dec. 13, 2002) in the Journal of Cardiothoracic and Vascular Anesthesia.


The study also showed although hemoglobin raffimer -- like other oxygen therapeutics or blood substitutes tested to date -- produced elevated blood pressures during surgery, it was the only significant side effect and was manageable.

?Our data suggests that hemoglobin raffimer, when used during bypass surgery, is well tolerated and may be effective in reducing blood transfusions,? said Duke anesthesiologist Steven Hill, M.D. ?Although elevated blood pressure was more frequent in patients given hemoglobin raffimer when compared to controls, aggressive management kept blood pressures under control.

?If we had an agent that could temporarily sustain oxygen delivery to the body during surgery without having to use donated blood, that could have significant long-term potential for our patients,? he said.

Hill said the importance of developing an effective oxygen therapeutic is not only because of the decreasing donor pool for human blood and fears of disease transmission, but also because transfused blood may lead to worse outcomes after heart surgery. He cited the results of a recent study conducted at the Medical College of Ohio, which showed that five years after heart surgery, 15 percent of patients receiving blood transfusions had died, compared to a seven percent mortality rate for those who didn?t receive a transfusion.

?It may be that transfusion is not as safe as we think,? Hill said. ?So if we had a product that we could pull off the shelf at any time, and not have to worry about the possibilities of any infectious agents or immune responses, that could be a major step forward in improving outcomes.?

Hemoglobin raffimer is produced by removing hemoglobin, an oxygen-carrying molecule, from human red blood cells that have ?expired,? or passed their 42-day shelf life. After 42 days, Hill explained, stored red blood cells begin to break down and are no longer used in human transfusions.

?For hemoglobin raffimer, the hemoglobin is extracted and the other components of the red blood cells are discarded,? Hill said. ?The hemoglobin is then heat-treated and filtered, which eliminates risks of infectious agents.?

In bypass procedures, some of a patient?s own blood may be removed just prior to being placed on the heart-lung machine -- which takes over for the heart during surgery. The blood is replaced by a colloid solution. Then, the patients? own blood can be returned at a later point during the surgery, preferably after blood loss has ceased. This blood preservation strategy is frequently used to reduce the need for transfused blood.

?To avoid transfusion during cardiac surgery, however, we do have to remove a significant amount of the patients? own blood,? Hill said. ?A hemoglobin-based oxygen carrier would provide additional circulating hemoglobin to facilitate safe removal of the patient?s blood and support oxygen delivery to the body during the three to four hours of surgery.?

In the Duke study, 60 patients undergoing coronary artery bypass operations at six U.S. medical centers were randomized to receive either varying doses of hemoglobin raffimer or colloid during surgery. Of those receiving hemoglobin raffimer, 44 percent did not need a blood transfusion, while 18 percent of the control group avoided transfusion. Other than elevated blood pressures, the researchers found no other significant negative side effects from the agent.

There are two other ongoing trials of hemoglobin raffimer -- a Phase III trial being conducted in Canada and the United Kingdom, as well as a Phase II trial in the U.S., which is examining the effectiveness of the agent at higher doses.

The clinical trial was funded by Hemosol, Inc., Toronto, which developed hemoglobin raffimer. Hill has no financial interest in Hemosol.

Joining Hill in the study were Katherine Grichnik, M.D., from Duke and Lewis Gottschalk, M.D., University of Texas Medical School, Houston.

contact sources :
Steven Hill , (919) 681-6614
Hill0012@mc.duke.edu

Richard Merritt | dukemed news
Further information:
http://dukemednews.org/news/article.php?id=6189
http://www.mc.duke.edu/

More articles from Health and Medicine:

nachricht NIST scientists discover how to switch liver cancer cell growth from 2-D to 3-D structures
17.11.2017 | National Institute of Standards and Technology (NIST)

nachricht High speed video recording precisely measures blood cell velocity
15.11.2017 | ITMO University

All articles from Health and Medicine >>>

The most recent press releases about innovation >>>

Die letzten 5 Focus-News des innovations-reports im Überblick:

Im Focus: A “cosmic snake” reveals the structure of remote galaxies

The formation of stars in distant galaxies is still largely unexplored. For the first time, astron-omers at the University of Geneva have now been able to closely observe a star system six billion light-years away. In doing so, they are confirming earlier simulations made by the University of Zurich. One special effect is made possible by the multiple reflections of images that run through the cosmos like a snake.

Today, astronomers have a pretty accurate idea of how stars were formed in the recent cosmic past. But do these laws also apply to older galaxies? For around a...

Im Focus: Visual intelligence is not the same as IQ

Just because someone is smart and well-motivated doesn't mean he or she can learn the visual skills needed to excel at tasks like matching fingerprints, interpreting medical X-rays, keeping track of aircraft on radar displays or forensic face matching.

That is the implication of a new study which shows for the first time that there is a broad range of differences in people's visual ability and that these...

Im Focus: Novel Nano-CT device creates high-resolution 3D-X-rays of tiny velvet worm legs

Computer Tomography (CT) is a standard procedure in hospitals, but so far, the technology has not been suitable for imaging extremely small objects. In PNAS, a team from the Technical University of Munich (TUM) describes a Nano-CT device that creates three-dimensional x-ray images at resolutions up to 100 nanometers. The first test application: Together with colleagues from the University of Kassel and Helmholtz-Zentrum Geesthacht the researchers analyzed the locomotory system of a velvet worm.

During a CT analysis, the object under investigation is x-rayed and a detector measures the respective amount of radiation absorbed from various angles....

Im Focus: Researchers Develop Data Bus for Quantum Computer

The quantum world is fragile; error correction codes are needed to protect the information stored in a quantum object from the deteriorating effects of noise. Quantum physicists in Innsbruck have developed a protocol to pass quantum information between differently encoded building blocks of a future quantum computer, such as processors and memories. Scientists may use this protocol in the future to build a data bus for quantum computers. The researchers have published their work in the journal Nature Communications.

Future quantum computers will be able to solve problems where conventional computers fail today. We are still far away from any large-scale implementation,...

Im Focus: Wrinkles give heat a jolt in pillared graphene

Rice University researchers test 3-D carbon nanostructures' thermal transport abilities

Pillared graphene would transfer heat better if the theoretical material had a few asymmetric junctions that caused wrinkles, according to Rice University...

All Focus news of the innovation-report >>>

Anzeige

Anzeige

Event News

Ecology Across Borders: International conference brings together 1,500 ecologists

15.11.2017 | Event News

Road into laboratory: Users discuss biaxial fatigue-testing for car and truck wheel

15.11.2017 | Event News

#Berlin5GWeek: The right network for Industry 4.0

30.10.2017 | Event News

 
Latest News

NASA detects solar flare pulses at Sun and Earth

17.11.2017 | Physics and Astronomy

NIST scientists discover how to switch liver cancer cell growth from 2-D to 3-D structures

17.11.2017 | Health and Medicine

The importance of biodiversity in forests could increase due to climate change

17.11.2017 | Studies and Analyses

VideoLinks
B2B-VideoLinks
More VideoLinks >>>